Cost-effectiveness of colorectal cancer screening - An overview

Best Practice and Research: Clinical Gastroenterology

Volumn 24, Issue 4, 2010, Pages 439-449

  Lansdorp Vogelaar, Iris ^a   Knudsen, Amy B ^b   Brenner, Hermann ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Capsule endoscopy; Colonography, Computed tomographic; Colonoscopy; Colorectal neoplasms; Cost benefit analysis; Mass screening; Occult blood; Sigmoidoscopy; Stool DNA

Indexed keywords

DNA;

CANCER SCREENING; CAPSULE ENDOSCOPY; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONSENSUS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; HEALTH PROGRAM; HUMAN; MEDICAL TECHNOLOGY; REVIEW; SCREENING TEST;

EID: 77956601358     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2010.04.004     Document Type: Article

References (91)

1. J.M. Wilson, and Y.G. Jungner Principles and practice of mass screening for disease Boletin de la Oficina Sanitaria Panamericana 65 4 1968 Oct 281 393
2. S.J. Goldie Public health policy and cost-effectiveness analysis J Natl Cancer Inst Monogr 31 2003 102 110 Chapter 15
3. S.B. Cantor Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment Med Decis Making 14 3 1994 Jul-Sep 259 265
4. D.H. Mark Visualizing cost-effectiveness analysis JAMA 287 18 2002 May 8 2428 2429
5. M.C. Weinstein How much are Americans willing to pay for a quality-adjusted life year? Med Care 46 4 2008 Apr 343 345
6. B. Hollingsworth, P.J. Dawson, and N. Maniadakis Efficiency measurement of health care: a review of non-parametric methods and applications Health Care Manag Sci 2 3 1999 Jul 161 172
7. M. Johannesson, and M.C. Weinstein On the decision rules of cost-effectiveness analysis J Health Econ 12 4 1993 Dec 459 467
8. Special report: fecal DNA analysis for colon cancer screening Technol Eval Cent Asses Program Exec Summ 21 6 2006 Aug 1 2
9. M. Deutekom, A.F. van Rijn, E. Dekker, H. Blaauwgeers, K. Stronks, and P. Fockens Uptake of faecal occult blood test colorectal cancer screening by different ethnic groups in the Netherlands Eur J Public Health 19 4 2009 Aug 400 402
10. J.D. Hardcastle, J.O. Chamberlain, M.H. Robinson, S.M. Moss, S.S. Amar, and T.W. Balfour Randomised controlled trial of faecal-occult-blood screening for colorectal cancer Lancet 348 9040 1996 Nov 30 1472 1477
11. O. Kronborg, C. Fenger, J. Olsen, O.D. Jorgensen, and O. Sondergaard Randomised study of screening for colorectal cancer with faecal-occult-blood test Lancet 348 9040 1996 Nov 30 1467 1471
12. C. Masseria Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment Eur J Health Econ Suppl. 1 2010 Jan;10 S41 S49
13. J.A. Shapiro, L.C. Seeff, T.D. Thompson, M.R. Nadel, C.N. Klabunde, and S.W. Vernon Colorectal cancer test use from the 2005 National Health Interview Survey Cancer Epidemiol Biomarkers Prev 17 7 2008 Jul 1623 1630
14. S.W. Vernon Participation in colorectal cancer screening: a review J Natl Cancer Inst 89 19 1997 Oct 1 1406 1422
15. J.S. Mandel, J.H. Bond, T.R. Church, D.C. Snover, G.M. Bradley, and L.M. Schuman Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study New Engl J Med 328 19 1993 May 13 1365 1371
16. S.J. Winawer, R.H. Fletcher, L. Miller, F. Godlee, M.H. Stolar, and C.D. Mulrow Colorectal cancer screening: clinical guidelines and rationale Gastroenterology 112 2 1997 Feb 594 642
17. B. Levin, D.A. Lieberman, B. McFarland, K.S. Andrews, D. Brooks, and J. Bond Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology Gastroenterology 134 5 2008 May 1570 1595 (Pubitemid 351615355)
18. U.S. Preventive Services Task Force Screening for colorectal cancer: U.S. preventive services task force recommendation statement Ann Int Med 149 9 2008 Oct 6
19. M. Pignone, S. Saha, T. Hoerger, and J. Mandelblatt Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. preventive services task force Ann Int Med 137 2 2002 Jul 16 96 104 (Pubitemid 34779153)
20. M. Parekh, A.M. Fendrick, and U. Ladabaum As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia Aliment Pharmacol Ther 27 8 2008 697 712
21. P.J. Pickhardt, C. Hassan, A. Laghi, A. Zullo, D.H. Kim, and S. Morini Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions Cancer 109 11 2007 Jun 1 2213 2221
22. S. Vijan, I. Hwang, J. Inadomi, R.K. Wong, J.R. Choi, and J. Napierkowski The cost-effectiveness of CT colonography in screening for colorectal neoplasia Am J Gastroenterol 102 2 2007 Feb 380 390
23. Zauber A, Knudsen AB, Rutter CM, Lansdorp-Vogelaar I, Savarino JE, van Ballegooijen M, et al. Cost-effectiveness of CT Colonography to screen for colorectal cancer; 2009.
24. C. Berchi, V. Bouvier, J.M. Reaud, and G. Launoy Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France Health Econ 13 3 2004 Mar 227 238
25. D. Gyrd-Hansen The relative economics of screening for colorectal cancer, breast cancer and cervical cancer Crit Rev Oncol Hematol 32 2 1999 Nov 133 144
26. C. Hassan, A. Zullo, A. Laghi, I. Reitano, F. Taggi, and P. Cerro Colon cancer prevention in Italy: cost-effectiveness analysis with CT colonography and endoscopy Dig Liver Dis 39 3 2007 Mar 242 250
27. L. Hristova, and M. Hakama Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017 Acta Oncol 36 Suppl. 9 1997 1 60
28. C. Lejeune, P. Arveux, V. Dancourt, S. Bejean, C. Bonithon-Kopp, and J. Faivre Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer Int J Technol Assess Health Care 20 4 2004 Fall 434 439 (Pubitemid 39491490)
29. D.A.L. Macafee, M. Waller, D.K. Whynes, S. Moss, and J.H. Scholefield Population screening for colorectal cancer: the implications of an ageing population Br J Cancer 99 12 2008 1991 2000
30. J. Norum Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy Ann Oncol 9 6 1998 Jun 613 618
31. A. Sieg, and H. Brenner Cost-saving analysis of screening colonoscopy in Germany Z Gastroenterol 45 9 2007 Sep 945 951
32. R.J. Steele, R. Gnauck, R. Hrcka, O. Kronborg, C. Kuntz, and P. Moayyedi Methods and economic considerations: group 1 report. ESGE/UEGF Colorectal Cancer-Public Awareness Campaign. The Public/Professional Interface Workshop: Oslo, Norway, June 20-22, 2003. fulfillment corporate Endoscopy 36 4 2004 Apr 349 353
33. P. Tappenden, J. Chilcott, S. Eggington, J. Patnick, H. Sakai, and J. Karnon Option appraisal of population-based colorectal cancer screening programmes in England Gut 56 5 2007 May 677 684 (Pubitemid 46662935)
34. D.K. Whynes, and F.O.B.S.T. Nottingham Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial J Med Screen 11 1 2004 11 15
35. L.S. Chen, C.S. Liao, S.H. Chang, H.C. Lai, and T.H. Chen Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16) J Med Screen 14 4 2007 191 199
36. M. Leshno, Z. Halpern, and N. Arber Cost-effectiveness of colorectal cancer screening in the average risk population Health Care Manag Sci 6 3 2003 Aug 165 174
37. T. Shimbo, H.A. Glick, and J.M. Eisenberg Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan Int J Technol Assess Health Care 10 3 1994 Summer 359 375
38. K.K. Tsoi, S.S. Ng, M.C. Leung, and J.J. Sung Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia Aliment Pharmacol Ther 28 3 2008 Aug 1 353 363
39. S.S. Wong, A.P. Leong, and T.Y. Leong Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach Stud Health Technol Inform 107 Pt 1 2004 104 110
40. G.H. Wu, Y.M. Wang, A.M. Yen, J.M. Wong, H.C. Lai, and J. Warwick Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries BMC Cancer 6 2006 136
41. B.A. O'Leary, J.K. Olynyk, A.M. Neville, and C.F. Platell Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy J Gastroenterol Hepatol 19 1 2004 Jan 38 47
42. G. Salkeld, G. Young, L. Irwig, M. Haas, and P. Glasziou Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia Aust N Z J Public Health 20 2 1996 Apr 138 143
43. C.A. Stone, R.C. Carter, T. Vos, and J. St John Colorectal cancer screening in Australia: An economic evaluation of a potential biennial screening program using faecal occult blood tests Aust New Zeal J Publ Health 28 3 2004 273 282
44. W.M. Flanagan, C. Le Petit, J.M. Berthelot, K.J. White, B.A. Coombs, and E. Jones-McLean Potential impact of population-based colorectal cancer screening in Canada Chronic Dis Can 24 4 2003 Fall 81 88
45. B. Macfarlane, R. Leicester, C. Romaya, and O. Epstein Colonoscopy services in the United Kingdom Endoscopy 31 6 1999 Aug 409 411
46. P.G. van Putten, M.E. van Leerdam, and E.J. Kuipers The views of gastroenterologists about the role of nurse endoscopists, especially in colorectal cancer screening Aliment Pharmacol Ther 29 8 2009 Apr 15 892 897
47. COUNCIL RECOMMENDATION of 2 December 2003 on cancer screening 2003 Council of the European Union
48. L. Hol, M.E. van Leerdam, M. van Ballegooijen, A.J. van Vuuren, H. van Dekken, and J.C. Reijerink Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy Gut 59 1 2010 Jan 62 68
49. N. Segnan, C. Senore, B. Andreoni, A. Arrigoni, L. Bisanti, and A. Cardelli Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates J Natl Cancer Inst 97 5 2005 Mar 2 347 357
50. M. Pignone, L. Russell, and J. Wagner Economic models of colorectal cancer screening in average-risk adults: workshop summary 2005 Institute of Medicine and National Research Council of the National Academies Washington DC
51. Cancer intervention and surveillance modeling network Available from http://cisnet.cancer.gov
52. J.E. Allison, I.S. Tekawa, L.J. Ransom, and A.L. Adrain A comparison of fecal occult-blood tests for colorectal-cancer screening New Engl J Med 334 3 1996 Jan 18 155 159
53. G. Castiglione, M. Zappa, G. Grazzini, A. Mazzotta, M. Biagini, and P. Salvadori Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer Br J Cancer 74 1 1996 Jul 141 144
54. V. Dancourt, C. Lejeune, C. Lepage, M.C. Gailliard, B. Meny, and J. Faivre Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms Eur J Cancer 44 15 2008 Oct 2254 2258
55. L. Guittet, V. Bouvier, N. Mariotte, J.P. Vallee, D. Arsene, and S. Boutreux Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population Gut 56 2 2007 Feb 210 214
56. N. Hoepffner, Y.M. Shastri, E. Hanisch, W. Rosch, J. Mossner, and W.F. Caspary Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study Aliment Pharmacol Ther 23 1 2006 Jan 1 145 154
57. K. Hughes, B. Leggett, C. Del Mar, J. Croese, S. Fairley, and J. Masson Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community Aust N Z J Public Health 29 4 2005 Aug 358 364
58. C.W. Ko, J.A. Dominitz, and T.D. Nguyen Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests Am J Med 115 2 2003 Aug 1 111 114
59. P. Rozen, J. Knaani, and Z. Samuel Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study Cancer 89 1 2000 Jul 1 46 52
60. A. Smith, G.P. Young, S.R. Cole, and P. Bampton Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia Cancer 107 9 2006 Nov 1 2152 2159
61. L.G. van Rossum, A.F. van Rijn, R.J. Laheij, M.G. van Oijen, P. Fockens, and H.H. van Krieken Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population Gastroenterology 135 1 2008 Jul 82 90
62. B.C. Wong, W.M. Wong, K.L. Cheung, T.S. Tong, P. Rozen, and G.P. Young A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population Aliment Pharmacol Ther 18 9 2003 Nov 1 941 946
63. M. Zappa, G. Castiglione, E. Paci, G. Grazzini, T. Rubeca, and P. Turco Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience Int J Cancer 92 1 2001 Apr 1 151 154
64. J.E. Allison, L.C. Sakoda, T.R. Levin, J.P. Tucker, I.S. Tekawa, and T. Cuff Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics J Natl Cancer Inst 99 19 2007 Oct 3 1462 1470
65. Zauber A, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: report to AHRQ and CMS from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN and SimCRC Models.2007.
66. D.C. Chung Stool DNA testing and colon cancer prevention: another step forward Ann Int Med 149 7 2008 Oct 7 509 510
67. Special report critical appraisal of CT colonography cost-effectiveness analyses Technol Eval Cent Asses Program Exec Summ 24 2 2009 Aug 1 2
68. C. Hassan, P. Pickhardt, A. Laghi, D. Kim, A. Zullo, and F. Iafrate Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: model simulation with cost-effectiveness analysis Arch Int Med 168 7 2008 696 705
69. Z. Fireman, and Y. Kopelman The colon-the latest terrain for capsule endoscopy Dig Liver Dis 39 10 2007 Oct 895 899
70. K. Tran Capsule colonoscopy: pillcam colon Issues Emerg Health Technol 106 2007 Oct 1 4
71. C. Hassan, A. Zullo, S. Winn, and S. Morini Cost-effectiveness of capsule endoscopy in screening for colorectal cancer Endoscopy 40 5 2008 May 414 421
72. L. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, and L. Clegg SEER Cancer Statistics Review, 1975-2001 2004 National Cancer Institute Available from http://seer.cancer.gov/csr/1975-2001/
73. E. Giovannucci Modifiable risk factors for colon cancer Gastroenterol Clin North Am 31 4 2002 Dec 925 943
74. S. Agrawal, A. Bhupinderjit, M.S. Bhutani, L. Boardman, C. Nguyen, and Y. Romero Colorectal cancer in African Americans Am J Gastroenterol 100 3 2005 Mar 515 523 [discussion 4]
75. I. Lansdorp-Vogelaar, M. van Ballegooijen, A.G. Zauber, R. Boer, J. Wilschut, and S.J. Winawer Individualizing colonoscopy screening by sex and race Gastrointest Endosc 70 1 2009 Jul 96 108 e1-24
76. C.P. Theuer, T.H. Taylor, W.R. Brewster, and H. Anton-Culver Gender and race/ethnicity affect the cost-effectiveness of colorectal cancer screening J Natl Med Assoc 98 1 2006 Jan 51 57
77. C.P. Theuer, J.L. Wagner, T.H. Taylor, W.R. Brewster, D. Tran, and C.E. McLaren Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States Gastroenterology 120 4 2001 Mar 848 856
78. E. Abrahams, G.S. Ginsburg, and M. Silver The personalized medicine coalition: goals and strategies Am J Pharmacogenomics 5 6 2005 345 355
79. W. Kalow Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine Pharmacogenomics J 6 3 2006 May-Jun 162 165
80. M.L. Brown, G.F. Riley, A.L. Potosky, and R.D. Etzioni Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer Med Care 37 12 1999 Dec 1249 1259
81. K.R. Yabroff, E.B. Lamont, A. Mariotto, J.L. Warren, M. Topor, and A. Meekins Cost of care for elderly cancer patients in the United States J Natl Cancer Inst 100 9 2008 May 7 630 641
82. A. Sonnenberg, F. Delco, and J.M. Inadomi Cost-effectiveness of colonoscopy in screening for colorectal cancer Ann Int Med 133 8 2000 Oct 17 573 584
83. D. Schrag The price tag on progress-chemotherapy for colorectal cancer New Engl J Med 351 4 2004 Jul 22 317 319
84. F.F. Kabbinavar, H.I. Hurwitz, J. Yi, S. Sarkar, and O. Rosen Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 2 2009 Jan 10 199 205
85. A. de Gramont, C. Tournigand, T. Andre, A.K. Larsen, and C. Louvet Adjuvant therapy for stage II and III colorectal cancer Semin Oncol 34 2 Suppl. 1 2007 Apr S37 S40
86. I. Lansdorp-Vogelaar, M. van Ballegooijen, A.G. Zauber, J.D. Habbema, and E.J. Kuipers Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening J Natl Cancer Inst 101 20 2009 Oct 21 1412 1422
87. S. Gupta Will test-specific adherence predict the best colorectal cancer screening strategy? Ann Int Med 150 5 2009 Mar 3 359 author reply -60
88. A.G. Zauber, I. Lansdorp-Vogelaar, A.B. Knudsen, J. Wilschut, M. van Ballegooijen, and K.M. Kuntz Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force Ann Int Med 149 9 2008 Nov 4 659 669
89. D.L. Miglioretti, C.M. Rutter, S.C. Bradford, A.G. Zauber, L.G. Kessler, and E.J. Feuer Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization Med Care 46 9 Suppl. 1 2008 Sep S91 S96
90. W. Atkin, P. Rogers, C. Cardwell, C. Cook, J. Cuzick, and J. Wardle Wide variation in adenoma detection rates at screening flexible sigmoidoscopy Gastroenterology 126 5 2004 May 1247 1256
91. A. Shaukat, C. Oancea, J.H. Bond, T.R. Church, and J.I. Allen Variation in detection of adenomas and polyps by colonoscopy and change over time with a performance improvement program Clin Gastroenterol Hepatol 7 12 2009 Dec 1335 1340